International Conference of the

Modernization of Chinese Medicine & Health Products

國際現代化中醫藥及健康產品會議

14-15/8/2025

Organiser 主辦機構

MCMIA 現代化中醫藥國際協會

Leading Collaborating Organisation 主要合作機構

HKTDC 香港貿發局

Collaborating Organisations 合作機構

香港中文大學 The Chinese University of Hong Kong

香港城市大學 City University of Hong Kong

香港浸會大學 HONG KONG BAPTIST UNIVERSITY

一帶一路中醫藥發展聯盟 The Belt and Road Alliance for Traditional Chinese Medicine

The Hong Kong Polytechnic University 香港理工大學

香港科技大學 The Hong Kong University of Science and Technology

香港大學 The University of Hong Kong

HKAIM

國際藥學會有限公司 International Association of Materia Medica Limited

International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) 2025

國際現代化中醫藥及健康產品會議 2025

Welcome Message

On behalf of the Modernized Chinese Medicine International Association (MCMIA), I welcome you all to the 24th International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM).

This year's conference is once again funded by the Professional Services Advancement Support Scheme under the Commerce and Economic Development Bureau of the Hong Kong SAR Government.

We would like to express our gratitude to the Hong Kong Trade Development Council and all collaborating institutions for their support of the conference over the past two decades.

These institutions include China Association of Chinese Medicine Experimental Pharmacology Association, City University of Hong Kong, Hong Kong Association for Integration of Chinese-Western Medicine, Hong Kong Baptist University, International Association of Materia Medica, The Belt and Road Alliance for Traditional Chinese Medicine, The Chinese University of Hong Kong, The Hong Kong Polytechnic University, The Hong Kong University of Science and Technology and The University of Hong Kong.

Each year, ICMCM brings together global experts in Chinese medicine to share cutting-edge research achievements, discuss the latest R&D trends in Chinese medicine and health products and national regulations on Chinese medicine and share industry success stories.

This year, the conference theme is "The Latest Research Progress in the Prevention and Treatment of Tumors, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", with more than 20 experts and scholars invited to share their research findings and experiences.

In line with MCMIA's long-standing commitment to promoting the modernisation, internationalisation, and industrialisation of Chinese medicine, the second day of the conference highlights industry success stories to not only provide an interactive platform for industry players, but also help the industry develop and grow in the years ahead.

ICMCM is held in a hybrid online-offline format, with simultaneous bilingual English-Mandarin interpretation provided to enable more industry peers to participate in this event.

As a superconnector linking Mainland China to the rest of the world, Hong Kong is actively strengthening its role under the Guangdong-Hong Kong-Macao Greater Bay Area Construction Plan for a Chinese Medicine Highland (2020-2025) in accordance with the country's 14th Five-Year Plan.

Since the simplification of the registration and approval process for traditional external Chinese patent medicines listed in Hong Kong and Macao was implemented in 2021, 13 Hong Kong-registered external Chinese patent medicines have been launched in the mainland.

Earlier this year, new arrangements were announced to extend the measures to oral Chinese patent medicines, further facilitating Hong Kong's Chinese patent medicine manufacturers to explore the mainland market and promoting the development of the Chinese medicine industry.

Hong Kong's first Chinese medicine hospital will start operating this year, and the Hong Kong SAR Government will also announce a Chinese medicine development blueprint by the end of the year.

Hong Kong's advantages can ensure it plays a leading role in advancing the global development of Chinese medicine, and I encourage you all to leverage our dynamic platform.

I wish you all a successful Conference.

Lawrence Lo
President
Modernized Chinese Medicine International Association (MCMIA)

歡迎辭

本人謹代表現代化中醫藥國際協會 (MCMIA)，歡迎各位出席第 24 屆「國際現代化中醫藥及健康產品會議」(ICMCM)。

今屆會議再次獲得香港特別行政區政府商務及經濟發展局轄下的專業服務協進支援計劃 (PASS) 資助舉辦，我們感謝香港貿易發展局以及所有合作機構 20 多年來對會議的支持。這些合作機構包括中華中醫藥學會中藥實驗藥理分會、香港城市大學、香港中西醫結合醫學會、香港浸會大學、國際藥學會、一帶一路中醫藥發展聯盟、香港中文大學、香港理工大學、香港科技大學及香港大學等。

ICMCM 每年雲集全球中醫藥領域專家，共同分享尖端科研成果及探討中醫藥及健康產品的最新研發趨勢、對各國中醫藥法規的解讀，以及業界的成功經驗。今年 ICMCM 的主題為「傳統醫藥防治腫瘤、炎症及心臟血管疾病的最新研究進展」，合共邀請超過 20 位專家和學者，分享研究成果及經驗。為貫徹 MCMIA 一向致力於推動中醫藥「現代化、國際化及產業化」的宗旨，會議的第二天將聚焦業界的成功經驗，為業界提供一個互動交流的平台，助力中醫藥產業未來持續發展及增長。

今次會議以線上線下融合模式舉行，同時亦提供雙語 (英語 / 普通話) 即時傳譯，務求讓更多業界同仁可以參與今次盛會。

作為連接中國內地與世界各地的「超級聯繫人」，香港在國家《十四五規劃綱要》的規劃下，積極強化在《粵港澳大灣區中醫藥高地建設方案（2020-2025 年）》的角色。自簡化港澳已上市傳統外用中成藥註冊審批流程由 2021 年實施至今，已有 13 款香港註冊外用中成藥於內地上市；今年初亦公布新安排將措施擴展至口服中成藥，進一步便利香港中成藥製造商開拓內地市場，推動中醫藥產業發展。香港首間中醫醫院將於今年投入服務，政府亦將於年底公佈中醫藥發展藍圖。香港的優勢能確保其在推動全球中醫藥發展方面發揮領導角色，我鼓勵大家善用這個充滿活力的平台。

我祝願各位在今屆的會議滿載而歸！

現代化中醫藥國際協會
會長
魯展雨

Welcome Message

Welcome to the 24th International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM), organised by the Modernized Chinese Medicine International Association together with the Hong Kong Trade Development Council and 10 scientific research institutions and industry associations.

With shifts in lifestyles and dietary habits, coupled with a growing ageing population, a growing number of people are suffering from cancer, cardiovascular and cerebrovascular diseases, and conditions associated with inflammation.

Traditional Chinese medicine has proven effective in preventing and treating these conditions, alleviating discomfort and shortening recovery times.

As such, this year's conference is aptly themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine".

At the conference, more than 20 scholars and experts from medical schools, research institutions, pharmaceutical companies and organisations in Mainland China, Hong Kong, Malaysia and Thailand will explore the latest developments in traditional Chinese medicine for the prevention and treatment of tumours, inflammation and cardiovascular and cerebrovascular diseases. They will also present their research findings and success cases.

The Hong Kong SAR Government is positioning Hong Kong as a launchpad for the internationalisation of Chinese medicine. This includes encouraging more large-scale Chinese medicine conferences, exhibitions and events to be held in the city to drive industry development, promote talent exchange, strengthen international ties and create an environment for innovations to thrive.

ICMCM has been making tremendous contributions towards such goals. For over 20 years, it has been a driving force, offering a prominent platform for industry professionals to network, share results in disease prevention and treatment, exchange insights on new developments and seize collaboration opportunities.

I wish you all a fruitful ICMCM.

Margaret Fong
Executive Director
Hong Kong Trade Development Council

歡迎辭

歡迎各位出席由現代化中醫藥國際協會（MCMIA）聯同香港貿易發展局，以及 10 間科研機構和行業協會攜手舉辦的第 24 屆「國際現代化中醫藥及健康產品會議」(ICMCM)。

隨着大眾的生活方式及飲食習慣轉變，加上長者人口增長，愈來愈多人患上癌症、心腦血管疾病及出現炎症。中醫藥已被證實有效預防及治療以上病症、緩解患者不適及縮短康復時間。有見及此，今年會議遂以「傳統醫藥防治腫瘤、炎症及心腦血管疾病最新研究進展」為主題。

超過 20 位來自中國內地、香港、馬來西亞及泰國的醫藥學院、科研機構、藥廠及藥業組織的學者及專家，於會議上將探討傳統中醫藥用於防治腫瘤、炎症及心腦血管疾病的最新發展，並公佈多項相關臨床研究結果及分享成功個案。

香港特別行政區政府近年致力推動香港成為中醫藥國際化的平台，包括鼓勵更多中醫藥大型會議及展覽等在港舉辦，以展示及帶動行業發展及人才交流，加強國際聯繫，創造有利的營商及創科環境，「國際現代化中醫藥及健康產品會議」早已為上述目標作出重大貢獻。在過去 20 多年來，會議為中醫藥業界提供平台，讓業內人士聚首一堂，探討防治疾病的成果及交流，一起把握合作機會。

我祝願各位在會議上滿載而歸。

香港貿易發展局總裁
方舜文

International Conference of the Modernization of Chinese Medicine & Health Products (ICMCM) 2025
國際現代化中醫藥及健康產品會議 2025
The Latest Research Progress in the Prevention and Treatment of Tumors, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine
傳統醫藥防治腫瘤、炎症及心腦血管疾病最新研究進展

Date & Time 日期及時間	: 14 / 8 / 2025 (Thursday 星期四) 15 / 8 / 2025 (Friday 星期五)	9:30am – 5:30pm 9:30am – 5:30pm
Venue 地點	: Room N101B, Hong Kong Convention and Exhibition Centre & Online Streaming 香港會議展覽中心會議室 N101B 及線上直播 (*Attendees are welcomed to participate in either format 歡迎參會人士以親身或線上出席*)	
Languages 語言	: English and Putonghua 英語及普通話 (*With simultaneous interpretation service 設即時傳譯服務*)	

CME Credits
註冊中醫進修學分 :

Day 1 第一天 – 14 / 8 / 2025 (Thursday 星期四)	
Morning Sessions 上午講座 (10:15 – 12:15) Afternoon Sessions 下午講座 (14:00 – 17:30)	合共 6 學分 Total 6 credits
Day 2 第二天 – 15 / 8 / 2025 (Friday 星期五)	
Morning Sessions 上午講座 (09:30 – 12:30) Afternoon Sessions 下午講座 (14:30 – 17:30)	合共 6 學分 Total 6 credits

參加者必須完整出席第一天或第二天研討會，每天可分別獲得 6 學分。 Click here for details 按此查看詳情

Registration 登記 : https://www.hktdc.com/event/icmcm/en

14/8/2025 (Thursday 星期四)

9:30 - 10:00 **Opening Ceremony** 開幕典禮
(*Tea Reception & Registration starts at 9am 招待茶會及登記於早上 9 時開始*)

Session 1: Keynote Speech
第一節 : 主題演講

Moderators 主持人 :

- **Prof. Hongxi XU**, Honorary Dean, Distinguished Professor, Shanghai University of Traditional Chinese Medicine
  國家中組部特聘專家、一帶一路中醫藥發展聯盟主席、上海中醫藥大學首席教授、中藥學院名譽院長 徐宏喜教授
- **Prof. Hongjie ZHANG, PhD**, Chair Professor, Associate Dean (Teaching and Learning), Cheung On Tak Endowed Professor in Chinese Medicine, School of Chinese Medicine, Hong Kong Baptist University
  香港浸會大學中醫藥學院 講座教授、副院長(教與學)、張安德中醫藥冠名教授 張宏杰教授

Remarks: The organiser reserves the right to make changes to the programme without prior notice
註：主辦機構保留對會議程序調動之權利而不作另行通知

10:15 - 10:55	**The Unique Role of HK in Modernisation and Internationalisation of Chinese Medicine** **香港在中醫藥創新和國際化的角色** **Dr. KO Wing-man, GBS, JP**, Chairman, TCM All-sector Hong Kong Centre 中醫藥全產業鏈香港中心主席 高永文醫生 **, GBS, JP**	
10:55 - 11:35	**Novel Biotech for Natural Products** 創新生物科技在天然產物研究中的應用 **Prof. Aiping LYU**, Vice-President (Research and Development) cum Dean of Graduate School, Hong Kong Baptist University 香港浸會大學 副校長 (研究及拓展) 暨 研究院院長 呂愛平院士	
11:35 - 12:15	**Research and Development of Evidence-based Herbal Medicines for Cancer Management - Challenges and Opportunities** **研發實証為本的抗癌中草藥—挑戰與機遇** **Prof. Clara Bik-San LAU**, Professor, Department of Pharmacology and Pharmacy & School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong 香港大學李嘉誠醫學院藥理及藥劑學系和中醫藥學院教授 **劉碧珊教授**	
12:15 - 14:00	**Lunch Break** 午膳時間	
	Session 2: The Latest Research Progress in the Prevention and Treatment of Tumors and Inflammation with Traditional Medicine 第二節：傳統醫藥防治腫瘤與炎症最新研究進展	
	Moderators 主持人 : - **Prof. FENG Yibin**, Professor and Director of School of Chinese Medicine, The University of Hong Kong 香港大學中醫藥學院院長及教授 **馮奕斌教授** - **Prof. Zhixiu LIN**, Director and Professor of School of Chinese Medicine, The Chinese University of Hong Kong 香港中文大學中醫藥學院院長、教授 **林志秀教授**	
14:00 - 14:30	**Basic Considerations for the Development and Approval of New TCM Drugs Targeing Tumor-Related Indications** **以治療腫瘤相關的適應症為目的的中藥新藥開發立項之基本考慮** **Prof. ZHANG Yongwen**, Professor, Nanjing University of Traditional Chinese Medicine 南京中醫藥大學 **張永文教授**	
14:30 - 15:00	**Clinical Research on the Treatment of Liver Cirrhosis and Liver Cancer Using Yiqi Huoxue Jiedu Tongluo Therapy** **益氣活血解毒通絡法防治肝硬化及肝癌的臨床研究** **Prof. Wenliang LYU**, Vice President of Guang'anmen Hospital, China Academy of Chinese Medical Sciences 中國中醫科學院廣安門醫院副院長 呂文良教授	

Remarks: The organiser reserves the right to make changes to the programme without prior notice
註：主辦機構保留對會議程序調動之權利而不作另行通知

15:00 - 15:30	**Advances in Therapeutic Agents Targeting Quiescent Cancer Cells** 針對靜止癌細胞的治療藥物研究進展 **Dr. Wan Najbah Nik Nabil**, Pharmacist, Malaysia 馬來西亞藥劑師 **萬娜芭博士**	
15:30 - 16:00	**Traditional Chinese Medicine Treatment of Vascular Cognitive Impairment** 中醫治療血管性認知障礙 **Mr. Peeraphong Lertnimitphun**, Traditional Chinese Medicine Doctor, HuaChiew TCM Hospital 泰國華僑中醫院中醫師 **陳江成先生**	
16:00 - 16:30	**Tea Break** 茶聚	
	Session 3: The Latest Research Progress in the Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases with Traditional Medicine 第三節：傳統醫藥防治心血管疾病最新研究進展	
	Moderator 主持人： - **Prof. Clara Bik-San LAU**, Professor, Department of Pharmacology and Pharmacy & School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong 香港大學李嘉誠醫學院藥理及藥劑學系和中醫藥學院教授 **劉碧珊教授**	
16:30 - 17:00	**Study on the Target and Mechanism of Traditional Chinese Medicine Components Based on Chemical Biology** 基於化學生物學的中藥成分標靶點和機制研究 **Prof. Lixia CHEN**, Professor PI and Doctoral Supervisor, Wuya Innovation College, Shenyang Pharmaceutical University 瀋陽藥科大學無涯創新學院 PI 教授、博士生導師 **陳麗霞教授**	
17:00 - 17:30	**Biosynthesis of Bioactive Compounds from Chinese Herbal Medicines** **中藥活性成分的發現及其生物合成研究** **Prof. Min YE**, Dean and Professor, School of Pharmaceutical Sciences, Peking University 北京大學藥學院院長、教授 **葉敏教授**	
	End of Day 1 Conference 第一天會議結束	
	15/8/2025 (Friday 星期五)	
	Session 4: Successful Cases Sharing (Part A) 第四節：成功個案分享 (一)	
	Moderators 主持人： - **Mr. Harry YEUNG Kwok Chun**, MCMIA Foundation 現代化中醫藥國際基金主席 **楊國晉先生** - **Mr. Edward YAU**, Vice President, Modernised Chinese Medicine International Association 現代化中醫藥國際協會副會長 **邱福榮先生**	

Remarks: The organiser reserves the right to make changes to the programme without prior notice
註：主辦機構保留對會議程序調動之權利而不作另行通知

09:30 - 10:00	**The Anti-cancer Effect and Mechanism of TCM Active Ingredient Tanshinone** **中藥活性成分丹參酮的抗癌效應及機制** **Prof. KAI Guoyin**, Director, Laboratory of Medicinal Plant Biotechnology, Vice Dean, Scientific Research Department, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University 浙江中醫藥大學藥學院、藥食植物活性成分與健康浙江省國際合作基地主任 **開國銀教授**	
10:00 - 10:30	**From Traditional Chinese Medicines to Modern Health Products: Applications and Breakthroughs** **從傳統中藥到現代大健康產品：應用與突破** **Ms. Ivy JIA**, General Manager, Tong Han Chun Tang Co. Ltd. 童涵春堂總經理 **賈曉薇女士**	
10:30 - 11:00	**Industrialisation Progress of Traditional Chinese Medicine Extract Granules** **中藥配方顆粒的產業化進展** **Dr. LIANG Li**, Marketing Director (Overseas), China Traditional Chinese Medicine Holdings Co Ltd - Tianjiang Pharmaceutical 中國中藥控股有限公司天江藥業市場總監 (海外) **梁鸝博士**	
11:00 - 11:30	**Chemistry and Potential Value of Endemic Medicinal Plant Resources in Central and West Africa** **中西非特有藥用植物資源化學與潛在價值研究** **Prof. ZHAO Ming**, Excecutive Dean of Pharmacy School, Nanjing University of Chinese Medicine 南京中醫藥大學藥學院執行院長 **趙明教授**	
11:30 - 12:00	**Scientific Interpretation of Traditional Chinese Medicine Principles: A New Strategy for the Study of Clinical Effective Traditional Chinese Medicine Formulas and Active Ingredient Mechanisms** **科學解讀中醫藥原理—臨床有效中藥複方及活性成分機制研究的新策略** **Prof. SUN Yang**, Professor, School of Life Sciences, Nanjing University; Director, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University 南京大學生命科學學院生物技術與藥學系主任 **孫洋教授**	
12:00 - 12:30	**Regulations and Progress on Traditional Chinese Medicine (TCM) Product Registration in Thailand** **中藥產品在泰國註冊相關法規** **Mr. Chattarin Ruchawapol**, Research and Development Supervisor, Henggengtang Pharmaceutical Co., Ltd. 恒庚堂藥業有限公司研發經理 **盧憲先生**	
12:30 - 14:30	**Lunch Break** 午膳時間	

Remarks: The organiser reserves the right to make changes to the programme without prior notice
註：主辦機構保留對會議程序調動之權利而不作另行通知

Session 5: Successful Cases Sharing (Part B)
第五節：成功個案分享 (二)

Moderators 主持人：

- **Prof. Vivian WONG, JP**, Vice President, Modernized Chinese Medicine International Association
  現代化中醫藥國際協會副會長 **黃譚智媛教授**
- **Prof. LEE Ming-yuen, Simon**, DoRCOcean & Chair Professor, Biomedical Sciences of The Hong Kong Polytechnic University
  香港理工大學中醫藥創新研究中心成員兼食品科學與營養學系講座教授
  李銘源教授

14:30 - 15:00	**Red Ginseng: Targeting Inflammation and Multi-Pathway Bioactivities - Pioneering New Strategies for Colorectal Cancer Prevention and Rehabilitation** **紅參抗炎機制與多靶點活性：從結腸炎干預開拓大腸癌防治與康復新視野** **Dr. ZHANG Bingwei**, Research Manager, Shanghai R&D Center, Korea Ginseng Corporation 韓國人參公社上海研發中心 研究經理 **張冰衛博士**	
15:00 - 15:30	**Clinical Efficacy Evaluation Study of Tuina Combined with Medicated Oil Massage in the Treatment of Non-Specific Low Back Pain** **推拿聯合活絡油膏摩治療非特異性下腰痛的臨床療效評價研究** **Dr. YUAN Man**, Assistant Professor, Shanghai University of Traditional Chinese Medicine 上海中醫藥大學中藥學院副教授 **袁滿博士**	
15:30 - 16:00	**From Zero to One: Modernisation and Branding of Rare Chinese Herbs** **從零到一：珍稀中草藥的現代化和品牌化** **Mr. Andy DU Hao**, Co-founder and CEO, Ginpact Health (Hong Kong) Company Limited 山參有約健康科技 (香港) 有限公司 聯合創始人及首席執行官 **杜浩先生**	
16:00 - 16:30	**Exploration in the Research of Polysaccharides in Chinese Medicines** **中藥多糖的研究挑戰與探索** **Prof. HAN Quanbin**, Professor, School of Chinese Medicine, Hong Kong Baptist University 上海中醫藥大學中藥學院副教授 **韓全斌教授**	
16:30 - 17:00	**TCM Theory Empowering the R&D and Post-Marketing Re-Evaluation of Dominant Chinese Materia Medica** **中醫藥理論賦能中藥優勢品種研發與上市後再評價** **Ms. LIN Na**, Lead Researcher, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences 中國中醫科學院中藥研究所首席研究員 **林娜女士**	
17:00 - 17:30	**A Soothing Cream Gel Improves the Range of Motion and Chronic Pain at Shoulder and Elbow: A Randomised, Double-blind and Placebo-Controlled Trial** **天然舒緩霜凝膠改善肩部和肘部的活動範圍並緩解慢性疼痛的臨床療效評價研究** **Prof. XIAN Yanfang Lisa**, Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong 香港中文大學醫學院中醫學院助理教授 **冼彥芳教授**	

End of Day 2 Conference 第二天會議結束

Remarks: The organiser reserves the right to make changes to the programme without prior notice
註：主辦機構保留對會議程序調動之權利而不作另行通知

ICMCM 2025 Organising Committee 籌委會

Prof. Clara Bik San LAU, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 劉碧珊教授

Ms. Denise SUEN, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 孫亮女士

Mr. Edward YAU, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 邱福榮先生

Mr. Harry YEUNG Kwok Chun, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 楊國晉先生

Conference Organising Committee 會議籌備委員會

Co-conference Chairmen 會議聯席主席

Prof. Hongxi XU, Honorary Dean, Distinguished Professor, Shanghai University of Traditional Chinese Medicine
國家中組部特聘專家、一帶一路中醫藥發展聯盟主席、上海中醫藥大學首席教授、中藥學院名譽院長 徐宏喜教授

Prof. Hongjie ZHANG, PhD, Chair Professor, Associate Dean (Teaching and Learning),
Cheung On Tak Endowed Professor in Chinese Medicine, School of Chinese Medicine, Hong Kong Baptist University
香港浸會大學中醫藥學院 講座教授、副院長（教與學）、張安德中醫藥冠名教授 張宏杰教授

Committee Members 委員會成員

Prof. FENG Yi Bin, The University of Hong Kong
香港大學 馮奕斌教授

Prof. HUANG Yu, City University of Hong Kong
香港城市大學 黃聿教授

Prof. LEE Ming-yuen, Simon, The Hong Kong Polytechnic University
香港理工大學 李銘源教授

Prof. Zhixiu LIN, The Chinese University of Hong Kong
香港中文大學 林志秀教授

Prof. Vivian TAAM WONG, JP, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 黃譚智媛太平紳士

Prof. Karl TSIM, Hong Kong University of Science and Technology
香港科技大學 詹華強教授

Mr. Harry YEUNG, Modernized Chinese Medicine International Association (MCMIA)
現代化中醫藥國際協會 楊國晉先生

(Name listed in alphabetical order 以英文姓氏順序排列)

Organiser 主辦機構：

MCMIA 現代化中醫藥國際協會

Leading Collaborating Organisation 主要合作機構：

HKTDC 香港貿發局

Collaborating Organisations 合作機構：

香港中文大學 The Chinese University of Hong Kong

香港城市大學 City University of Hong Kong

香港浸會大學 HONG KONG BAPTIST UNIVERSITY

一帶一路中醫藥發展聯盟
The Belt and Road Alliance for Traditional Chinese Medicine

THE HONG KONG POLYTECHNIC UNIVERSITY 香港理工大學

香港科技大學 THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

香港大學 The University of Hong Kong

HKAIM

國際藥學會有限公司
International Association of Materia Medica Limited

Supporting Organisations 支持機構 :

Associação dos Investigadores Praticantes e Promotores da Medicina Chinesa de Macau
澳門中醫藥學會

Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited
港九中醫師公會有限公司

China Association of Chinese Medicine (CACM)
中華中醫藥學會

Chinese Medicine Merchants Association Limited
香港中藥聯商會有限公司

Consortium for Globalization of Chinese Medicine
中藥全球化聯盟

Federation of Hong Kong Industries
香港工業總會

Good Practice in Traditional Chinese Medicine Research Association
中醫藥規範研究學會

Hong Kong Biotechnology Organisation
香港生物科技協會

Hong Kong Chinese Medicine Pharmacists Association
香港中藥藥劑師協會

Hong Kong Chinese Patent Medicine Manufacturers' Association
香港中華製藥總商會

Hong Kong Registered Chinese Medicine Practitioners Association
香港註冊中醫學會

Kowloon Chamber of Commerce
九龍總商會

Malaysian Chinese Medical Association
馬來西亞中醫總會

People's Government of Anguo City
安國市人民政府

Pharmaceutical and Chinese Medicine Professionals Association
中西藥業專業人員協會

Sin-Hua Herbalists' and Herb Dealers' Promotion Society Limited
新華中醫中藥促進會有限公司

The Chinese General Chamber of Commerce
香港中華總商會

The Chinese Manufacturers' Association of Hong Kong
香港中華廠商聯合會

The Hong Kong Health Food Association
香港保健食品協會

The Hong Kong Institute of Biotechnology Limited
香港生物科技研究院有限公司

The Hong Kong Professional Institute of Chinese Medicine Medicated Meal & Fooda
香港中醫藥膳專業學會

The Hong Kong Society of Chinese Medicines
香港中藥學會

上海市藥理學會中藥藥理專業委員會

**Listed in Organisations' alphabetical order 排名以機構英文字母為序*

This material / event is funded by the Professional Services Advancement Support Scheme of the Government of the Hong Kong Special Administrative Region
此物品 / 活動由香港特別行政區政府的專業服務協進支援計劃資助。

Session 1
第一節

Keynote Speech
主題演講

The Unique Role of HK in Modernisation and Internationalisation of Chinese Medicine
香港在中醫藥創新和國際化的角色

Dr. KO Wing-man, GBS, JP, Chairman, TCM All-sector Hong Kong Centre
中醫藥全產業鏈香港中心主席 高永文醫生 , GBS, JP

Abstract 摘要

Hong Kong's Chinese medicine has developed significantly in recent years. Under the framework of "one country, two systems", Hong Kong becomes an important platform for innovation and internationalisation of Chinese medicine, with great potential in education, scientific research, clinical services, production, testing and certification, trade, and international exchange, etc. As a trading centre for Chinese herbal medicines, Hong Kong attracts buyers from both domestic and internationally, driving market demand growth. Hong Kong's Chinese medicine regulatory system is well-developed, with comprehensive testing and certification services that ensure product safety and enhance credibility, and strengthens international competitiveness, positioning Hong Kong as a key leader in the global Chinese medicine arena.

過去 20 年，中醫藥在香港特區政府的高度重視之下，取得顯著發展。無論在中醫藥人材培訓、科研、臨床服務、中藥產業、標準制定等方面，發展潛力巨大。香港作為國際貿易中心，能夠吸引海內外商家，推動中藥材市場健康發展。香港中醫藥管理制度完善，檢測認證服務確保產品安全及提升信譽，增強國際競爭力。希望在一國兩制之下，把香港發展成中醫藥國際化的橋頭堡，掌握中醫藥的國際話語權。

Speaker's Biography 講者簡介

Non-official Member of the Executive Council of Hong Kong
Member of the Standing Committee of the National Committee of the Chinese People's Political
Chairman of TCM All-sector Hong Kong Centre
Former Secretary of Food and Health of Hong Kong

高永文醫生是一名骨科專科醫生，畢業於香港大學醫學院，獲澳洲新南威爾斯大學健康行政碩士學位，英國愛丁堡皇家外科醫學院士、香港醫學專科學院骨科及社會醫學院士資格。2002 年，成為英國皇家內科醫學院公共衞生醫學科院士，並於 2018 年、2020 年獲香港浸會大學、香港公開大學頒授榮譽社會科學博士。

高醫生現任香港特區行政會議非官守議員，全國政協全國委員會常務委員，政協潮州市委員會常委，並擔任聯合國兒童基金會香港委員會委員，香港潮屬社團總會常務副主席，香港中國商會常務副會長及中醫藥全產業鏈香港中心主席。

於 2012 年 7 月至 2017 年 6 月期間，高醫生擔任香港特別行政區食物及衞生局局長，亦曾任香港防癌會主席及香港紅十字會總監。高醫生雖身為西醫，但自小對中醫藥產生了濃厚興趣，不但修讀了中醫藥相關課程，更積極推動中醫藥的傳承、創新及發展。
高醫生於 2001 年獲委任為太平紳士，及分別於 2008 年及 2017 年獲頒銅紫荊星章及金紫荊星章。

Novel Biotech for Natural Products
創新生物科技在天然產物研究中的應用

Prof. Aiping LYU, Vice-President (Research and Development) cum Dean of Graduate School, Hong Kong Baptist University
香港浸會大學 副校長 (研究及拓展) 暨 研究院院長 呂愛平院士

ABSTRACT 摘要

Novel drug discovery from natural products with biotechnology
A great progress has been made in biotechnology, and there are still some shortages in new drug discovery from natural products. By approaching new biotechnology might be a better way to develop new drugs from natural products. Some new technological approaches, including Protac, aptamer, peptide, gut microbiota, new materials in drug delivery will be discussed for their potential roles in new drug discovery from natural products.

創新生物科技在天然產物研究中的應用
生物技術領域已取得重大進展，但在天然產物新藥研發方面仍存在不足。運用新型生物技術可能是開發天然產物藥物的更優途徑。本文將探討包括蛋白降解靶向嵌合體（Protac）、適配體、多肽、腸道微生物群、新型藥物遞送材料在內的多項技術在天然產物新藥研發中的潛在作用。

Speaker's Biography 講者簡介

Prof Aiping Lyu is currently the Vice-President (Research and Development) and Dr Kennedy Wong Endowed Professor in Chinese Medicine at Hong Kong Baptist University. He has been elected as a Foreign Member of the Academia Europaea in 2022 in recognition of his sustained academic excellence in systems medicine. Lyu's current research focuses on the field of systems medicine, where he integrates Chinese medicine and Western medicine while applying advanced techniques in life sciences and data sciences. Specifically, he is dedicated to the novel re-classification of rheumatoid arthritis, aiming to identify more precise therapeutics based on new sub-groupings of patients through a combination treatment approach using existing drugs. His research has further delved into the dynamics of network biomarkers for re-classification and the interaction of combined drugs for precise treatment.

Prof. Lyu's contributions to academia are substantial, with 600 academic papers published in renowned journals such as *Nature Medicine, Nature Review in Drug Discovery, Nature Communications*, and *Briefings in Bioinformatics*, covering a wide range of areas in integrative medicine. Over the years, Prof Lyu had obtained over 60 patents from his research innovation. His research excellence has been acknowledged with the Highly Cited Researcher in 2023 by Clarivate Analytics.

呂愛平博士，香港浸會大學副校長（研究與拓展）暨研究院院長，黃英豪博士冠名中醫藥講座教授。全球高被引科學家（2023）。歐洲科學院（Academia Europaea）外籍院士。國家傑出青年基金獲得者。國

際標準化組織中醫藥技術委員會中方代表團團長。曾任國家自然科學基金委員會醫學科學部專家咨詢委員會委員、中國中西醫結合學會副會長、國際中醫藥規範化研究會（Good Practice in Traditional Chinese Medicine Research Association）主席；長期探索病證結合診療模式下新的治療策略和新藥研發策略，以及中醫藥國際標準和臨床實踐指南的制修訂。發表包括 Nature Medicine，Nature Communication，Nature Review Drug Discovery 等國際知名雜誌論文 600 多篇。獲得中國和美國專利 60 餘項。

Research and Development of Evidence-based Herbal Medicines for Cancer Management - Challenges and Opportunities
研發實証為本的抗癌中草藥—挑戰與機遇

Prof. Clara Bik-San LAU, Professor, Department of Pharmacology and Pharmacy & School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong
香港大學李嘉誠醫學院藥理及藥劑學系和中醫藥學院教授　劉碧珊教授

Abstract 摘要

Herbal medicines have long been used worldwide for treating chronic disorders such as cancer. Prof. Clara Lau has been focusing on evidence-based research of herbal medicines and natural products in cancer management for more than two decades. In this talk, she will illustrate the challenges and opportunities of exploring multi-component and multi-target nature of herbal medicines, as well as potentials of lead natural compounds, using various experimental systems of breast and colon cancer. Beneficial evidences from bench to bedside of a medicinal herb for treating esophageal cancer will also be presented. It is anticipated that scientific findings from these studies will support the use of herbal medicines in cancer management and increase the acceptance by cancer patients and cancer care providers.

草藥在世界各地已被廣泛應用於治療長期病患，例如癌症。在過去二十多年，劉碧珊教授集中於實証為本的抗癌草藥及天然產物的研究。是次演講她將闡述有關在乳癌及大腸癌臨床前研究多成份多靶點的草藥及具潛力的天然化合物過程中遇到的挑戰與機遇。同時亦介紹一種草藥在食道癌治療的新藥效發現，從實驗室到臨床的研究進程。研究成果提供了科研實証以鞏固草藥在癌症治療的應用，以及提高癌症患者和治療團隊對草藥的接受程度。

Speaker's Biography 講者簡介

Professor Clara Lau has over 30 years' expertise in Pharmacology of herbal medicines research, focusing on anti-cancer herbs/natural products, beneficial herb-drug combinations, and integrative medicine. Published over 290 refereed journal articles (H-index 51) and 11 book chapters, and editor of one book series. She is ranked by Clarivate Analytics among the top 1% of researchers worldwide by citations in 2024. Currently, she serves as non-official member of HKSAR Chinese Medicine Development Committee (CMISC), Secretary General of Consortium for Globalisation of Chinese Medicine (CGCM), Past President of Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA), and Council Member of MCMIA.

劉教授從事草藥學研究超過 30 年。主要研究範疇包括抗癌的草藥和天然產物，草藥西藥聯用的藥效以及中西醫藥結合。她在國際性同行評審期刊中發表超過 290 篇文章 (H-index 51) ，出版 11 篇書籍章節，編輯一套叢書。2024 年被列為科睿唯安世界首 1% 頂級科學家。劉教授是現任香港特別行政區醫務衛生局中醫中藥發展委員會中藥業小組委員會委員、中藥全球化聯盟秘書長、中醫藥規範研究學會前會長及現代化中醫藥國際協會董事。

Session 2
第二節

The Latest Research Progress in the Prevention and Treatment of Tumors and Inflammation with Traditional Medicine
傳統醫藥防治腫瘤與炎症最新研究進展

Basic Considerations for the Development and Approval of New TCM Drugs Targeing Tumor-Related Indications
以治療腫瘤相關的適應症為目的的中藥新藥開發立項之基本考慮

Prof. ZHANG Yongwen, Professor, Nanjing University of Traditional Chinese Medicine
南京中醫藥大學 張永文教授

Abstract 摘要

The development of new traditional Chinese medicine (TCM) drugs based on TCM theory represents systematic research oriented toward clinical value. This R&D framework strictly adheres to the "three-pronged" guiding principle (TCM theory, human application experience, clinical trials). For intervention strategies targeting tumor-related indications, TCM-based drug development primarily centers on a "regulatory" therapeutic philosophy.

基於中醫藥理論的中藥新藥開發是以臨床價值為導向的系統性研究，其研發框架嚴格遵循＂三結合＂（中醫理論 - 人用經驗 - 臨床試驗）指導原則。在腫瘤相關適應症的干預策略上，中藥新藥研發主要採用＂調節＂為核心的治療理念。

Speaker's Biography 講者簡介

ZHANG Yongwen, Ph.D., Researcher and Second-Level Professor at the School of Pharmacy, Nanjing University of Chinese Medicine. Member of the 11th and 12th Specialised Committees on Chinese Materia Medica (Natural Medicines) under the Chinese Pharmacopoeia Commission.

張永文，博士，南京中醫藥大學藥學院研究員，二級教授。國家藥典委員會第 11、12 屆中藥材（天然藥物）專委會委員。

Clinical Research on the Treatment of Liver Cirrhosis and Liver Cancer Using Yiqi Huoxue Jiedu Tongluo Therapy
益氣活血解毒通絡法防治肝硬化及肝癌的臨床研究

Prof. Wenliang LYU, Vice President of Guang' anmen Hospital,
China Academy of Chinese Medical Sciences
中國中醫科學院廣安門醫院副院長 呂文良教授

Abstract 摘要

The pathological progression from liver fibrosis to cirrhosis and ultimately to hepatocellular carcinoma represents a major focus and challenge in the prevention and treatment of chronic liver diseases. Traditional Chinese medicine (TCM) offers unique advantages in delaying or interrupting this pathological process. We have translated theoretical insights on the therapeutic principles of "tonifying Qi and activating blood," as well as "detoxifying and dredging meridians," into evidence-based research, developed a series of representative herbal formulas, and successfully achieved their clinical translation. These efforts have advanced innovation in the integrated treatment of liver diseases through the combination of TCM and Western medicine.

肝纖維化 - 肝硬化 - 肝癌的病理演進是慢性肝病的防治重點與難點，中醫藥在延緩或阻斷病理進程方面具有獨特優勢。我們將益氣活血、解毒通絡法的理論研究成果引向實證研究，創制系列代表方並實現代表方藥的臨床轉化應用，推動中西醫結合防治肝病領域的創新發展。

Speaker's Biography 講者簡介

Wenliang Lyu, M.D., Ph.D. is a second-level professor, doctoral supervisor, and leading authority in Traditional Chinese Medicine (TCM) in China. Currently serving as Vice President of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, he holds key leadership positions including Vice President and Secretary-General of the Chinese Association of the Integration of Traditional and Western Medicine and Executive Council Member of the Chinese Medical Association. His pioneering research focuses on integrative medicine approaches for chronic liver diseases and gastrointestinal disorders. With an outstanding academic record, he has led over 30 national-level research projects (including National Key R&D Programs), published more than 200 high-impact papers, and served as chief editor for 19 authoritative monographs, making significant contributions to advancing TCM research and clinical practice.

呂文良，醫學博士、博士生導師，二級教授，首都中醫榜樣人物，中國中西醫結合學會副會長、秘書長，中華醫學會常務理事，中國中醫科學院廣安門醫院副院長。專注慢性肝病、胃病等的中西醫結合防治研究，主持國家重點研發計劃等課題 30 餘項，發表論文 200 餘篇，主編專著 19 部。

Advances in Therapeutic Agents Targeting Quiescent Cancer Cells
針對靜止癌細胞的治療藥物研究進展

Dr. Wan Najbah Nik Nabil, Pharmacist, Malaysia
馬來西亞藥劑師 萬娜芭博士

Abstract 摘要

（只提供英文版本）

Quiescent cancer cells (QCCs) can reversibly enter the G0 phase, allowing them to evade chemotherapy and radiotherapy, which primarily target proliferating cells. Upon reactivation, QCCs may contribute to cancer progression, recurrence, and metastasis. Understanding the mechanisms regulating their survival and reactivation is critical for developing targeted therapies. Four strategies have been proposed: inducing quiescence in proliferating cells, suppressing QCC reactivation, directly eliminating QCCs, and reactivating them to enhance sensitivity to conventional treatments. As tumors consist of both proliferative cells and QCCs, integrating QCC-targeting approaches into clinical practice requires further refinement for optimal therapeutic outcomes.

Speaker's Biography 講者簡介

（只提供英文版本）

She is a pharmacist currently working at the National Pharmaceutical Regulatory Agency, Malaysia. Previously, she worked in the Traditional and Complementary Medicine (T&CM) Unit at National Cancer Institute (NCI) and Putrajaya Hospital. She holds a Bachelor of Pharmacy from University Kebangsaan Malaysia, and a Master of Applied Science from RMIT University, Australia. She earned her PhD from Shanghai University of Traditional Chinese Medicine, focusing on the cytotoxic effects of a compound from Garcinia oligantha on quiescent cancer cells.

Traditional Chinese Medicine Treatment of Vascular Cognitive Impairment
中醫治療血管性認知障礙

Mr. Peeraphong Lertnimitphun, Traditional Chinese Medicine Doctor,
HuaChiew TCM Hospital
泰國華僑中醫院中醫師 陳江成先生

Abstract 摘要

Cognitive function refers to the brain's processes involved in planning, concentration, memory, reasoning, decision-making, communication, and intellectual abilities. Impairments in cognitive function, known as Cognitive Deficit or Cognitive Impairment, can disrupt daily life, affecting planning, memory, attention, movement, and communication. Vascular disease, especially stroke, is a major contributor, leading to Vascular Cognitive Impairment (VCI).

In Traditional Chinese Medicine (TCM), cognitive function is linked to the concept of "Shen" (神), leading to symptoms similar to Cognitive Impairment. The TCM approach to treating VCI includes herbal medicine, which has shown promise in clinical studies. Various herbal formulas and acupoints have demonstrated efficacy in improving cognitive function and reducing inflammation markers in VCI patients. Additionally, improvements have been observed in assessments such as the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).

This review aims to consolidate current knowledge on the TCM treatment of VCI, highlighting the therapeutic potential of herbal medicine and acupuncture in managing VCI.

認知功能是指大腦在計劃、集中注意力、記憶、推理、決策、溝通和智力能力方面的過程。認知功能的缺陷，稱為認知缺陷或認知障礙，可能會影響日常生活，影響計劃、記憶、注意力、運動和溝通能力。血管性疾病，尤其是中風，是導致血管性認知障礙（VCI）的主要因素。

在中醫理論中，認知功能與「神」的概念有關，神的功能失常導致類似於認知障礙的症狀，故中醫對 VCI 的治療具有潛力。中醫治療 VCI 的臨床研究顯示其具有潛在的療效。多種中藥配方和針灸穴位在改善認知功能和降低 VCI 患者中炎症標誌物方面表現出顯著療效。此外，中醫藥對評估量表如，簡易智力狀態檢查（MMSE）和蒙特利爾認知評估（MoCA）等評估量表具有顯著性改善。本文旨在闡述近年中醫藥治療 VCI 的治療，強調中藥和針灸在管理 VCI 方面的治療潛力。

Speaker's Biography 講者簡介

Occupation

TCM doctor—Huachiew TCM hospital
Member of TCM academic—Huachiew TCM hospital
Member of TCM clinical research and development committee—Huachiew TCM hospital
Editorial member of Thailand Journal of Traditional Chinese Medicine
ISO/TC 249 Committee member

Education:

2017-2020 Doctoral of Chinese Materia Medica
—Shanghai University of Traditional Chinese Medicine
2014-2017 Master of Acupuncture moxibustion and Tuina
—Shanghai University of Traditional Chinese Medicine
2009-2014 Bachelor of Traditional Chinese Medicine
—Shanghai University of Traditional Chinese Medicine

Published paper:

Lertnimitphun, Peeraphong et al. "Safranal Alleviated OVA-Induced Asthma Model and Inhibits Mast Cell Activation." Frontiers in immunology vol. 12 585595. 20 May. 2021, doi:10.3389/fimmu.2021.585595(IF=7.561)

Lertnimitphun, Peeraphong et al. "Safranal Alleviates Dextran Sulfate Sodium-Induced Colitis and Suppresses Macrophage-Mediated Inflammation." Frontiers in pharmacology vol. 10 1281. 1 Nov. 2019, doi:10.3389/fphar.2019.01281(IF=3.845)

職業

華僑中醫院—中醫師
華僑中醫院—中醫藥學術委員
華僑中醫院—中醫臨床研究與發展
泰國中醫藥雜誌—編委
ISO/TC 249 委員

學歷：

2017-2020 中藥學博士學位—上海中醫藥大學
2014-2017 針灸推拿學碩士學位—上海中醫藥大學
2009-2014 中醫學學士學位—上海中醫藥大學

發表論文：

Lertnimitphun, Peeraphong et al. "Safranal Alleviated OVA-Induced Asthma Model and Inhibits Mast Cell Activation." Frontiers in immunology vol. 12 585595. 20 May. 2021, doi:10.3389/fimmu.2021.585595(IF=7.561)

Lertnimitphun, Peeraphong et al. "Safranal Alleviates Dextran Sulfate Sodium-Induced Colitis and Suppresses Macrophage-Mediated Inflammation." Frontiers in pharmacology vol. 10 1281. 1 Nov. 2019, doi:10.3389/fphar.2019.01281(IF=3.845)

Session 3
第三節

The Latest Research Progress in the Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases with Traditional Medicine
傳統醫藥防治心血管疾病最新研究進展

Study on the Target and Mechanism of Traditional Chinese Medicine Components Based on Chemical Biology
基於化學生物學的中藥成分標靶點和機制研究

Prof. Lixia CHEN, Professor PI and Doctoral Supervisor, Wuya Innovation College, Shenyang Pharmaceutical University
瀋陽藥科大學無涯創新學院 PI 教授、博士生導師 陳麗霞教授

Abstract 摘要

The researcher has developed a novel Targeted Degradomics technology based on PROTAC, pioneering the application of PROTAC technology for target identification of traditional Chinese medicine (TCM) components. This achievement provides a new chemical biology tool for "drug-to-target" discovery. Integrated with structural pharmacology approaches, the platform has led to the discovery of multiple TCM-derived lead compounds and candidate molecules targeting anti-tumor and anti-inflammatory pathways.

報告人建立了基於 PROTAC 的靶向降解組學新技術（Targeted Degradomics），首次利用 PROTAC 技術進行中藥成分靶點的鑒定，提供「以藥找靶」的化學生物學新工具。結合結構藥理學的研究平台，發現了多個靶向抗腫瘤、抗炎等的中藥來源先導化合物和候選分子。

Speaker's Biography 講者簡介

Lixia Chen, Professor PI and doctoral supervisor at Wuya Innovation College, Shenyang Pharmaceutical University, the "Young Changjiang Scholar" of the Ministry of Education. She has been ranked among the World's Top 2% Scientists for five years from 2020 to 2024, and has been included in the "Career-long Impact" list in 2024. She focuses on the targets and mechanisms of traditional Chinese medicine and natural medicines based on chemical biology. She has hosted 6 projects funded by the National Natural Science Foundation of China. She has published over 200 SCI papers, including 1 hot topic paper, 4 highly cited papers, and more than 8000 citations, with an H-factor of 43 (scopus). She serves as the deputy editor in chief of Acta Materia Medica, and the editorial board member of Bioorganic Chemistry.

陳麗霞，瀋陽藥科大學無涯創新學院 PI 教授，博士生導師，教育部 " 青年長江學者 "。2020-2024 連續 5 年入選全球前 2% 頂尖科學家排名榜單，2024 年入選「終身影響力」榜單。主要從事基於化學生物學進行中藥及天然藥物作用靶點和機制研究。主持國家自然科學基金項目 6 項，發表 SCI 論文 200 餘篇，其中熱點論文 1 篇，高被引論文 4 篇，被引用 8000 多次，H 因子 43(scopus)。擔任《Acta Materia Medica》副主編、《Bioorganic Chemistry》編委。

Biosynthesis of Bioactive Compounds from Chinese Herbal Medicines
中藥活性成分的生物合成研究

Prof. Min YE, Dean and Professor, School of Pharmaceutical Sciences, Peking University
北京大學藥學院院長、教授 葉敏教授

Abstract 摘要

A series of biosynthetic investigations have been conducted on pharmacologically active natural products from traditional Chinese medicines that possess complex structures and are challenging to obtain through traditional methods. This study identified a series of key biosynthetic enzymes and elucidated the biosynthetic pathways. Through protein structure analysis, their catalytic functions were optimised, ultimately enabling the complete biosynthesis of bioactive compounds.

針對藥理活性明確、結構複雜、難以獲取的中藥成分，開展了一系列生物合成研究。鑒定生物合成關鍵酶，解析生物合成途徑，解析蛋白結構，優化酶的催化功能，並在煙草等體系實現異源全合成。

Speaker's Biography 講者簡介

Min Ye is a Professor at the School of Pharmaceutical Sciences, Peking University, and a Principal Investigator at the State Key Laboratory of Natural and Biomimetic Drugs. His research focuses on the bioactive constituents of traditional Chinese medicine and their biosynthesis. He currently serves as the Chair of the Medicinal Plant and Plant Medicine Committee of the Botanical Society of China, and Executive Editor for the Journal of Ethnopharmacology.

葉敏，北京大學藥學院教授，天然藥物及仿生藥物全國重點實驗室 PI。主要研究領域為中藥藥效物質及其生物合成。中國植物學會藥用植物及植物藥專業委員會主任，*J Ethnopharmacol* 雜誌執行編輯。

Session 4
第四節

Successful Cases Sharing (Part A)
成功個案分享 (一)

The Anti-cancer Effect and Mechanism of TCM Active Ingredient Tanshinone
中藥活性成分丹參酮的抗癌效應及機制

Prof. KAI Guoyin, Director, Laboratory of Medicinal Plant Biotechnology, Vice Dean, Scientific Research Department, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University
浙江中醫藥大學藥學院、藥食植物活性成分與健康浙江省國際合作基地主任 開國銀教授

Abstract 摘要

Ovarian cancer (OC), a common malignancy in the female reproductive system, has the highest mortality rate among gynecological cancers. Dihydrotanshinone I (DHT) from Salvia miltiorrhiza, was found to exhibit cytotoxicity against ovarian cancer with unclear mechanism. Here we reported that DHT increased ROS accumulation, decreased mitochondrial membrane potential and activated oxidative stress in OC cells. Proteomic analysis suggests that DHT suppresses OC growth via the autophagy-lysosome pathway, with SORT1 identified as a critical target. CO-IP and CETSA analysis reveal that DHT directly targets and promotes ubiquitination-dependent degradation of SORT1. This positions DHT as a promising therapeutic candidate for OC.

卵巢癌是女性生殖系統中常見的惡性腫瘤。二氫丹參酮 I（DHT）對卵巢癌症具有很好活性，但機制尚不清楚。我們發現 DHT 可通過增加卵巢癌細胞中 ROS 來抑癌；還發現 DHT 可促進 SORT1 的泛素化降解而抑癌，DHT 是一種有前景的候選藥物。

Speaker's Biography 講者簡介

Dr. Guoyin Kai, Professor, Deputy Director of the Research Department in Zhejiang Chinese Medical University, National Leading Talent of Ten Thousand Talents, National Excellent Youth, Chief Scientist of the National Key R&D Program, Director of the Zhejiang Province International Science and Technology Cooperation Base for Medicinal and Edible Plant Active Ingredients and Health, Director of the Zhejiang Province Key Laboratory of Traditional Chinese Medicine Resource Innovation and Transformation, mainly engaged in research on traditional Chinese medicine biotechnology. Published over 200 SCI papers in Trends in Biotechnology, Journal of Advanced Research, PNAS, etc., and was continuously selected as a highly cited Chinese scholar by Elsevier from 2022 to 2024.

開國銀：浙江中醫藥大學二級教授，博導，科研部副部長，國家萬人領軍人才，國家優青，國家重點研發計劃首席科學家，浙江省藥食植物活性成分與健康國際科技合作基地主任，浙江省中藥資源創新與轉化中醫藥重點實驗室主任，主要從事中藥生物技術等研究。在 Trends in Biotechnology、Journal of Advanced Research、PNAS 等發表 SCI 論文 200 餘篇 , 2022-2024 連續入選 Elsevier 中國高被引學者。

From Traditional Chinese Medicines to Modern Health Products: Applications and Breakthroughs
從傳統中藥到現代大健康產品：應用與突破

Ms. Ivy JIA, General Manager, Tong Han Chun Tang Co. Ltd.
童涵春堂總經理 賈曉薇女士

Abstract 摘要

At the intersection of the “Healthy China” initiative and the global boom in functional foods, traditional Chinese medicine (TCM) is urgently called to transition from the pharmacy cabinet into everyday life.

This report adopts an evidence-based approach to reinterpret the efficacy of Chinese herbs, aligning traditional prescriptions with modern health demands and daily consumption scenarios. It explores the integration of TCM with contemporary trends such as ready-to-eat formats, compound formulations, and digital technologies. Through policy, market, and technology case studies, the report presents a complete pathway from prescription to product, offering a replicable model for the modern development of TCM in the era of holistic health.

在“健康中國”戰略與全球功能食品熱潮交匯之際，中藥亟需從“藥櫃”走向“日常生活”。本次報告以循證醫學方法重新解碼本草功效，中藥傳統方在大健康需求場景和人群的生活化匹配，從而與即食化、複配化、數位化等現代技術想融合，並以政策、市場與技術的案例展示從方劑到產品的完整鏈路，為中醫藥在大健康時代的現代化開發提供可複製範式。

Speaker's Biography 講者簡介

Ms Ivy JIA

Dec.2015--Sep.2022 **General Manager, Innovative Product and Marketing Center, Yuyuan Inc. Ltd.**
Oct.2022--Present **General Manager, Tong Han Chun Tang Co. Ltd.**

Xiaowei Jia currently serves as the head of a century-old TCM brand in Shanghai. She is dedicated to interdisciplinary research at the intersection of classical theories of traditional Chinese medicine and modern nutritional science, with a focus on the contemporary interpretation and industrialisation of the “medicine and food homology” theory. Her work explores innovative approaches to applying traditional prescriptions within the broader health and wellness context. In the past two years, she has led her team in developing over 30 types of Chinese-style tonic foods, published three related research papers, and filed five invention patents. She has also participated in the drafting and revision of industry standards related to medicine-food homology, contributing a replicable model for integrating traditional medicine into modern nutritional science.

賈曉薇女士

2015.12—2022.09	豫園股份	C2M 及好產品行銷中心 總經理
2022.10—至今	童涵春堂	公司總經理

現任上海百年國藥老字號企業負責人，致力於中醫藥經典理論與現代營養科學交叉研究，聚焦於「藥食同源」理論的現代闡釋與產業化路徑，探索傳統方劑在大健康場景下創新與產業化。近兩年，帶領團隊主持開發 30 餘款中式養生功能食品，發表相關論文 3 篇，申請發明專利 5 項；並參藥食同源相關行業標準的起草修訂，為傳統醫藥融入現代營養科學提供了可複製的實踐範式。

Industrialisation Progress of Traditional Chinese Medicine Extract Granules
中藥配方顆粒的產業化進展

Dr. LIANG Li, Marketing Director (Overseas),
China Traditional Chinese Medicine Holdings Co Ltd - Tianjiang Pharmaceu
中國中藥控股有限公司天江藥業市場總監（海外） 梁鸝博士

Abstract 摘要

After 30 years of development – from pilot research and trial production to full-scale regulation (since 2021) – China's TCM Extract Granules industry has achieved three major breakthroughs:

1. **Standardisation Deepened:** Chiese Pharmacopoeia released **342 national standards** (as of Jan 2025), while provinces established **over 700 regional standards**, building full-process quality control;
2. **Industrial Expansion Accelerated: 73 registered manufacturers** nationwide, growing market scale, covered by health plans in **22 provinces**, with **13 provinces** launching centralised procurement;
3. **Global Breakthroughs:** Spearheaded **ISO/USP standards**, exported to **30+ countries**, becoming a key driver for TCM's global reach.

Moving forward, it will keep leading high-quality growth across TCM's industrial chain, setting a model case for modernizing traditional medicine.

中藥配方顆粒產業歷經三十年發展，從科研試點、生產試點到全面規範化監管（2021 年結束試點），實現三大突破：

1. **標準化縱深推進**：國家藥典委累計發佈 **342 項國家標準**（截至 2025 年 1 月），各省制定**超 700 項省級標準**，構建全過程質控體系；
2. **產業化加速擴容**：全國 73 家備案企業佈局生產，產業規模持續增長，醫保覆蓋 22 省，13 省啓動掛網採購；
3. **國際化突破顯著**：主導制定 ISO 國際標準、美國藥典標準；出口 30 余國，成中藥「走出去」關鍵支點。未來將持續引領中藥全產業鏈高質量發展，為中醫藥現代化提供典範。

Speaker's Biography 講者簡介

Dr. Liang Li

Current Positions:

- Overseas Market Director, *Tianjiang Pharmaceutical* (China TCM Holdings)
- Secretary, *Ben Cao Du Shu Hui* (Hong Kong)
- Appointed Expert:
  - o China-ASEAN Traditional Medicine Cooperation

  - o China-Brazil TCM International Cooperation Base
- Council Member, *World Federation of Chinese Medicine Societies (WFCMS)*:
  - o Manchu Medicine Specialty Committee
  - o Post-Marketing Evaluation Committee

Specializing in:

TCM international trade; Global TCM culture promotion & public education; Overseas product registration; Herbal authentication & quality research.

梁鸝，博士

現任

- 中藥控股天江藥業海外市場總監；
- 本草讀書會秘書長（香港）；
- 中國 - 東盟傳統藥物合作項目特聘專家；
- 中國 - 巴西中醫藥國際合作基地中醫藥衛生合作項目特聘專家；
- 世界中醫藥學會聯合會滿藥專業委員會理事；
- 世界中醫藥學會聯合會中藥上市後研究與評價專業委員會理事。

主要從事：中醫藥國際貿易；中醫藥文化海外推廣及公眾教育；中醫藥產品海外註冊；中藥鑒定及品質評價研究。

Chemistry and Potential Value of Endemic Medicinal Plant Resources in Central and West Africa
中西非特有藥用植物資源化學與潛在價值研究

Prof. ZHAO Ming, Excecutive Dean of Pharmacy School,
Nanjing University of Chinese Medicine
南京中醫藥大學藥學院執行院長 趙明教授

Abstract 摘要

The genus Icacin is restricted to Central and West Africa and possesses diverse ethnomedicinal traditions. It is rich in (9β-H)-pimarane diterpenoids, which are rare in nature. To date, over 70% of the (9β-H)-pimarane-type natural products discovered have been identified by our research team. We have uncovered a series of novel skeleton types and compounds derived from (9β-H)-pimarane diterpenoids from Icacina plants, while also discovering their remarkable biological activities, including plant growth inhibition, antiviral, antitumor, and antimicrobial properties.

茶茱萸屬植物局限分布於中西非地區，具有多樣性的民族藥用傳統，富含自然界罕見的 (9β-H)- 海松烷二萜類成分。迄今發現的 (9β-H)- 海松烷類天然產物，70% 以上均由我們團隊研究發現。我們發現了一系列衍生於 (9β-H)- 海松烷二萜的新骨架類型與新成分，同時發現了這些成分具備優異的生物活性，包括植物生長抑制、抗病毒、抗腫瘤、抑菌活性等。

Speaker's Biography 講者簡介

Ming Zhao

Professor at Nanjing University of Chinese Medicine, Doctoral Advisor, Jiangsu Distinguished Professor, Lead Principal Investigator of Jiangsu's "Double Innovation" Research Team, and Second-Tier Scholar in Jiangsu's "333 Talent Project".

Currently serving as Executive Dean of the School of Pharmacy at Nanjing University of Chinese Medicine and as Deputy Secretary-General of the Expert Committee on Traditional Chinese Medicine and Natural Medicinal Resources under the Chinese Society of Natural Resources. Core faculty member of the "National Huang Danian-model Teaching Team", a prestigious recognition for excellence in higher education.

His research program centers on elucidating the bioactive components and therapeutic mechanisms of traditional Chinese medicines and natural products, along with advancing the sustainable development and utilization of TCM resources through innovative chemistry approaches. He maintains an active international collaboration investigating unique medicinal resources from Central and West Africa. His scholarly output includes over 120 peer-reviewed publications in leading journals such as Engineering, ACS Applied Materials & Interfaces, Pharmacological Research, Organic Letters, Organic Chemistry Frontiers, and Journal of Natural Products, with more than 100 papers indexed in SCI. Since his appointment at Nanjing University of Chinese Medicine,

he has secured three general program grants from the National Natural Science Foundation of China, led a sub-project of the National Key R&D Program, directed a Jiangsu "Double Innovation" Team initiative, and contributed to a National Key R&D Program research task.

趙明
南京中醫藥大學藥學院

南京中醫藥大學教授，博士生導師，江蘇省特聘教授，江蘇省“雙創團隊”帶頭人，江蘇省“333 工程”二層次培養對象。現任南京中醫藥大學藥學院執行院長，兼任中國自然資源學會中藥及天然藥物資源研究專業委員會副秘書長。“全國高校黃大年式教學團隊”核心骨幹。

主要從事中藥及天然藥物藥效物質基礎及作用機制、中藥資源化學與資源循環利用等領域的研究，並基於國際合作長期開展中西非特有藥用資源研究。迄今已在 *Engineering, ACS Applied Materials & Interfaces, Pharmacological Research, Organic Letters, Organic Chemistry Frontiers, Journal of Natural Products* 等期刊上發表學術論文 120 餘篇，包括 SCI 論文 100 餘篇。2016 年入職至今，先後主持國家自然科學基金面上項目 3 項、國家重點研發計劃項目子課題 1 項、江蘇省“雙創團隊”創新項目 1 項，參與國家重點研發計劃任務 1 項。

Scientific Interpretation of Traditional Chinese Medicine Principles: A New Strategy for the Study of Clinical Effective Traditional Chinese Medicine Formulas and Active Ingredient Mechanisms

科學解讀中醫藥原理 — 臨床有效中藥複方及活性成分機制研究的新策略

Prof. SUN Yang, Professor, School of Life Sciences, Nanjing University;
Director, Department of Biotechnology and Pharmaceutical Sciences,
School of Life Sciences, Nanjing University
南京大學生命科學學院生物技術與藥學系主任 孫洋教授

Abstract 摘要

（只提供中文版本）

炎症是多種複雜慢性疾病的共性病理基礎，發現並挖掘重大慢病防治的新技術、新手段成為了其團隊長期研究方向。 本次報告介紹了其團隊在炎症慢性化機制與化學干預、炎癌轉化等方面的研究成果，以及利用現代科學解讀中醫藥原理，促進中醫藥傳承創新發展的努力。 報告以具體案例解析入手，詳細介紹了中藥活性成分靶標確證方法、單細胞多組學科技，展示了這些科技在中藥研究中的應用，如環黃芪醇、大麻二酚等中藥活性成分的作用機制研究，以及參白解毒方對結直腸腺瘤癌變的抑制作用等。

Speaker's Biography 講者簡介

（只提供中文版本）

孫洋，南京大學藥理學教授、博導，教育部重大人才工程計畫特聘教授、國家優青。 現任南京大學生命科學學院黨委委員、生物技術與藥學系主任、醫藥生物技術全國重點實驗室課題組長。 長期從事炎症性疾病的病理機制與中醫藥調控研究。 擔任中國藥理學會抗炎免疫藥理專委會副主任委員、APSB 執行副主編。 以通訊作者（含共同）發表 Nat Aging、Nat Commun、EMBO Mol Med、Arthritis Rheumatol、Adv Sci、JITC 等論文 90 餘篇。 主持包括聯合基金重點專案在內的國自然 9 項和國家重點研發計畫課題 1 項。 曾獲教育部自然科學獎一等獎 2 項（排名第 2 和 3）。

Regulations and Progress on Traditional Chinese Medicine (TCM) Product Registration in Thailand
中藥產品在泰國註冊相關法規

Mr. Chattarin Ruchawapol, Research and Development Supervisor,
Henggengtang Pharmaceutical Co., Ltd.
恒庚堂藥業有限公司研發經理 盧憲先生

Abstract 摘要

Traditional Chinese Medicine (TCM) is increasingly recognized in Thailand, particularly within the fields of public healthcare and wellness-related services. The regulatory framework and development improved the registration of TCM products in the country. The foundational legislation of medicinal substances, including traditional and herbal preparations, is the Drug Act B.E. 2510 (1967). To promote innovation and streamline regulatory procedures for herbal products, the Herbal Product Act B.E. 2562 (2019) was enacted, emphasizing safety, efficacy, and quality assurance. The Thai Food and Drug Administration (Thai FDA) oversees the registration process, which requires applicants to submit detailed information on manufacturing processes, product composition, and evidence of safety or clinical efficacy. TCM products are classified under modern drugs, traditional medicines, or herbal products. Bilateral cooperation between Thailand and China has played a key role in fostering regulatory harmonization and mutual understanding. Nevertheless, challenges persist, including non-uniform evaluation standards, documentation language issues, and the integration of traditional medical principles with scientific validation. Continued policy advancement and cross-border collaboration are essential to improve regulatory efficiency and to strengthen consumer confidence in TCM products within the Thai context.

傳統中醫藥（TCM）在泰國日益受到認可，特別是在公共衛生和健康服務領域。泰國的監管體系和相關發展有助於推動中醫藥產品的註冊工作。管理藥品（包括傳統和草本製劑）的基礎法律為《藥品法》（B.E. 2510，1967 年）。為促進草藥產品的創新並簡化監管程序，泰國於 2019 年製定了《草藥產品法》（B.E. 2562），重點強調產品的安全性、有效性和質量保障。泰國食品藥品監督管理局（Thai FDA）負責監督註冊流程，申請者需提交關於生產工藝、產品成分以及安全性或臨床有效性的詳細資料。中醫藥產品根據其配方和用途，被歸類為現代藥品、傳統藥品或草藥產品。泰中兩國之間的雙邊合作在促進法規協調與增進相互理解方面發揮了重要作用。然而，仍面臨一些挑戰，包括評估標準不統一、文獻資料的語言問題，以及傳統醫學理念與現代科學驗證之間的融合問題。持續推進政策改革與跨國合作，對於提升監管效率和增強泰國消費者對中醫藥產品的信心至關重要。

Speaker's Biography 講者簡介

（只提供英文版本）

Education:

2016-2019: B.Sc. in Chemistry, Mahidol University International College, Thailand

2020-2023: M.Sc. in Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, China

2024-present: B.Sc in Traditional Chinese Medicine, Huachiew Chalermprakiet University, Thailand

Publications at school:

"Clock Reaction Revisited: Catalyzed Redox Substrate-Depletive Reactions" in 2019
https://doi.org/10.1021/acs.jchemed.8b00547 (IF: 2.39 in 2019)
"Natural Products and Their Derivatives against Human Herpesvirus Infection" in 2021
https://doi.org/10.3390/molecules26206290 Molecules (IF: 4.93 in 2021)
"A review on computational approaches that support the researches on traditional Chinese medicines (TCM) against COVID-19" in 2022
https://doi.org/10.1016/j.phymed.2022.154324 Phytomedicine (IF: 5.34 in 2022)

Rewards at school:

2020: Received "Cai Tong De Scholarship" as welcoming new international student
2022: Received "New Development Scholarship" as publishing two literature reviews

Work experience:

Research and development at Henggengtang Pharmaceutical Co., Ltd. Since 2020

Session 5
第 5 節

Successful Cases Sharing (Part B)
成功個案分享 (二)

Red Ginseng: Targeting Inflammation and Multi-Pathway Bioactivities - Pioneering New Strategies for Colorectal Cancer Prevention and Rehabilitation
紅參抗炎機制與多靶點活性：從結腸炎干預開拓大腸癌防治與康復新視野

Dr. ZHANG Bingwei, Research Manager, Shanghai R&D Center, Korea Ginseng Corporation
韓國人參公社上海研發中心 研究經理 張冰衛博士

Abstract 摘要

The occurrence of colorectal cancer (CRC) is intricately linked to chronic inflammatory conditions such as inflammatory bowel disease (IBD). Red ginseng, as a valuable traditional Chinese medicine, provides a new direction for multi process health management of colorectal cancer patients due to its various biological activities - inhibiting inflammation, neutralizing oxidative stress, modulating immune responses, alleviating fatigue, and restoring balance to gut microbiota. This report synthesises evidence from preclinical animal studies and clinical human trials to comprehensively illuminate red ginseng's pivotal role in CRC prevention, adjuvant therapeutic synergy, and postoperative recovery.

癌症（CRC）的發生與炎症性腸病（IBD）等慢性炎症疾病密切相關。紅參作為傳統藥食同源物質，憑藉其多方面的生物活性——抑制炎症、中和氧化應激、調節免疫反應、緩解疲勞和恢復腸道微生物群平衡——為大腸癌患者多過程健康管理提供了新方向。本報告綜合了臨床前動物研究、臨床人體試驗的證據，全面闡明了紅參在 CRC 預防、輔助協同治療和術後恢復中的關鍵作用。

Speaker's Biography 講者簡介

As the research manager of the Shanghai R&D Center of Korea Ginseng Corporation, **Zhang Bingwei** is mainly responsible for the research on the efficacy of red ginseng and the regulation and standardisation of health food. Her work focuses on three areas:

- **Research management of the efficacy of red ginseng:** 1) Mechanistic research on red ginseng's anti-fatigue effects and safety certification; 2) Optimisation of hypolipidemic formulations combining red ginseng with hawthorn/cassia seed; 3) Clinical validation of red ginseng high saponins for menopausal syndrome management.
- **Functional Product Innovation:** 1) Development of red ginseng-synbiotic preparations for intestinal immunomodulation and anti-inflammation; 2) Design of metabolic disease-preventive complexes (patent-pending).
- **Industrial Translation Support:** 1) End-to-end management of health food registration; 2) Establishment of group standards/industry consensus.

Key Intellectual Property

Patent CN117796524A: "*Composition containing red ginseng, hawthorn, and cassia seed extracts for preventing, ameliorating or treating metabolic diseases*". Its innovation is that for the first time, Red Hawthorn and Cassia Seed are applied to blood lipid regulation. At present, the pilot test and registration inspection have been completed, and it has entered the health food registration application stage.

Representative Clinical Trial

Intervention Study on Red Ginseng on the Health of Perimenopausal Women (2023-2024)

The study employed a randomised, double-blind, placebo-controlled design (n=100). Primary assessment tools included the Kupperman Index (KI) for menopausal symptom evaluation, the Beck Depression Inventory-II (BDI-II) for mood assessment, and the Athens Insomnia Scale (AIS) for sleep quality analysis. Key outcomes demonstrated a 39% reduction in vasomotor symptom frequency (hot flashes/night sweats) alongside a 20% enhancement across sleep quality indices.

作為韓國人蔘公社上海研發中心的研究經理，**張冰衛**主要負責開展紅參功效研究和保健食品法規與標準化，她的工作集中在三個領域：

- **紅參的功效研究管理**：1）紅參抗疲勞作用機理研究及安全認證；2）紅參與山楂 / 決明子聯用降脂製劑的優化；3）紅參高皂苷提取物治療更年期綜合征的臨床驗證。
- **功能產品創新**：1）紅參腸道免疫調節抗炎合生製劑的研製；2）代謝性疾病預防複合物的設計（專利申請中）。
- **產業轉化支撐**：1）保健食品註冊備案全流程管理；2）團體標準 / 行業共識制定。

關鍵知識產權

- “包括紅參、山楂果和決明子提取物的，用於預防、改善或治療代謝疾病的組合物”（專利號：CN117796524A）。其創新點是首次將紅參與山楂、決明子協同應用於血脂調節。目前已完成中試和註冊檢驗，進入保健食品註冊申報階段。

代表性臨床試驗

- 紅參對於圍絕經期婦女健康的干預研究（2023-2024）

  該研究採用了隨機、雙盲、安慰劑對照的設計（n=103）。主要評估工具包括用於評估更年期症狀的庫珀曼指數（KI）、用於評估情緒的貝克抑鬱量表第二版（BDI-II）以及用於分析睡眠品質的雅典失眠量表（AIS）。研究結果顯示，血管舒縮症狀（如潮熱和夜間盜汗）的發生率減少了 39%，同時睡眠品質指標提高了 20%。

Clinical Efficacy Evaluation Study of Tuina Combined with Medicated Oil Massage in the Treatment of Non-Specific Low Back Pain
推拿聯合活絡油膏摩治療非特異性下腰痛的臨床療效評價研究

Dr. YUAN Man, Assistant Professor, Shanghai University of Traditional Chinese Medicine
上海中醫藥大學中藥學院副教授 袁滿博士

Abstract 摘要

This study evaluated the clinical efficacy of Tuina combined with Flying Eagle Medicated Oil massage in the treatment of non-specific low back pain (NSLBP) through a randomised controlled trial. The results showed that, compared with Tuina with water, the combined therapy was more effective in relieving pain, relaxing muscles, and improving functional outcomes. Infrared thermography and compound profiling further supported its therapeutic potential. The findings suggest that this integrated approach is a safe and effective intervention with promising prospects for clinical application.

本研究通過隨機對照試驗，評估推拿聯合飛鷹活絡油膏摩在治療非特異性下腰痛（NSLBP）中的臨床療效。結果顯示，與推拿加水相比，推拿聯合活絡油的療法在緩解疼痛、放鬆肌肉及改善功能指標方面更具優勢。紅外熱成像與成分分析結果進一步證實其治療潛力。研究表明，該整合療法作為一種安全、有效的干預手段，在臨床應用中具有良好前景。

Speaker's Biography 講者簡介

Dr. Yuan Man is an Associate Researcher at the School of Pharmacy, Shanghai University of TCM. Her work focuses on TCM pharmacology and industrial transformation. She leads one NSFC project, participated in two national major new drug development programs, has published 24 papers (H-index 10), holds 2 patents, and co-authored 4 books. She currently serves as a youth committee member of the Chinese Society of Experimental Pharmacology of TCM, Director of the Anti-Virus Branch, and Vice Secretary-General of the Cultural and Creative Industry Branch of the World Federation of Chinese Medicine Societies.

袁滿博士，上海中醫藥大學藥學院副研究員，長期從事中藥藥理研究與產業轉化工作，主持國家自然科學基金項目 1 項，參與國家重大新藥創制專項 2 項，發表論文 24 篇（H 指數 10），授權專利 2 項，參編著作 4 部。現兼任中華中醫藥學會中藥實驗藥理分會青年委員、世界中聯抗病毒專業委員會理事、文創產業分會副秘書長等職。

From Zero to One: Modernisation and Branding of Rare Chinese Herbs
從零到一：珍稀中草藥的現代化和品牌化

Mr. Andy DU Hao, Co-founder and CEO, Ginpact Health (Hong Kong) Company Limited
山參有約健康科技（香港）有限公司 聯合創始人及首席執行官 杜浩先生

Abstract 摘要

The "King of Herbs", wild ginseng, exhibits significant differences in composition and efficacy compared to cultivated ginseng, with price disparities reaching up to ten thousand-fold. By applying advanced fermentation techniques that simulate the natural aging process of wild ginseng over decades, cultivated ginseng can be efficiently upgraded to closely resemble its wild variant in quality. Through branded products, this rare herbal treasure is made accessible to ordinary households.

“百草之王”野山參與普通種植人參成份和功效差異顯著，價格相差可達萬倍。利用特定發酵技術模擬野山參在土壤裡數十年成份變化過程，將普通種植人參高效轉化為野山參精華，並通過品牌化產品讓珍稀本草飛入尋常百姓家。

Speaker's Biography 講者簡介

Andy Du, HKICPA
CEO, GINPACT HEALTH (HONG KONG) COMPANY LIMITED
Investor, STREAM HILL ANGELS

Andy holds a B.Eng. degree from Zhejiang University and a M.Phil. degree from The Chinese University of Hong Kong. He was a professional investor managing a portfolio of nearly 100 companies totaling several billion USD. Andy is a beneficiary and enthusiast of traditional Chinese medicine (TCM). In 2024, he co-founded GINPACT with scientists and angel investors, focusing on the accessibility and globalisation of rare herbal products.

杜浩
山參有約健康科技（香港）有限公司，行政總裁
溪山天使匯投資人

浙江大學本科，香港中文大學碩士，香港註冊會計師。曾參與股權投資數百億元、近百家企業。中醫藥受益者、愛好者。2024 年與生物學家、天使投資人聯合創辦山參有約，致力於珍稀本草普惠化和全球化。

Exploration in the Research of Polysaccharides in Chinese Medicines
中藥多糖的研究挑戰與探索

Prof. HAN Quanbin, Professor, School of Chinese Medicine, Hong Kong Baptist University
香港浸會大學中醫藥學院 韓全斌教授

Abstract 摘要

Research on polysaccharides faces three main challenges: 1. Structural identification of polysaccharides; 2. Qualitative and quantitative analysis of polysaccharides; 3. Bioavailability of orally administered polysaccharides. Our research group has conducted exploratory studies on Dendrobium polysaccharides and Astragalus polysaccharides in these three areas. Firstly, based on the research example of Dendrobium polysaccharides, we proposed a purity standard for polysaccharides based on enzyme diagnostics and completed model studies using polysaccharide standards. Secondly, we developed qualitative and quantitative analysis methods based on polysaccharide and oligosaccharide markers, enabling the qualitative and quantitative analysis of specific polysaccharides in herb formulations and biological samples. Finally, using these analytical methods, we discovered a pathway for the intestinal lymphatic absorption of orally administered polysaccharides, providing new insights into the bioavailability of orally administered polysaccharides.

多糖的研究面臨著三個困難：一 . 多糖的結構鑒定；二 . 多糖的定性定量分析；三 . 口服多糖的生物利用度。本課題組以鐵皮石斛多糖和黃芪多糖為例，在上述三個方面開展了一些探索研究。首先是根據鐵皮石斛多糖的研究實例，提出了基於酶診斷的多糖純度標準，並利用多糖標準品完成了模型研究；其次是研發了基於多糖標誌物和寡糖標誌物的定性定量分析方法，實現了在中藥復方和生物樣本中對特定多糖的定性和定量分析；最後利用這些分析方法，發現了一條口服多糖經腸淋巴吸收的途徑，為口服多糖的生物利用提供了新的思路。

Speaker's Biography 講者簡介

Prof. Han Quanbin currently serves as the Director of the Research Center for Herb Polysaccharides and Intestinal Immunity at Hong Kong Baptist University, Editor-in-Chief of Phytochemical Analysis, Member of Biology and Medicine Panel of the Hong Kong Research Grants Council, and founder of the Hong Kong Authentication Cenrtre of Valuable Chinese Medicines. His main research interests focus on the chemistry, quality control, and biological activity of herb polysaccharides. He has published 200+ SCI papers (40 as the first author), with more than 8,000 citations, a Google Scholar H-index of 54, and holds over 20 national and international patents, with 18 technology transfers. He has been ranked among the top 2% of scientists globally for several consecutive years.

韓全斌教授目前擔任香港浸會大學中藥多糖和腸道免疫研究中心主任、Phytochemical Analysis 主編、香港研究資助局生物醫藥組評委、香港名貴中藥檢定中心創辦人等。目前的主要研究興趣為中藥多糖的化

學、質控及生物活性研究。在天然藥物有效成分和質量控制領域，共發表SCI論文200餘篇（第一作者40篇），總引用8000+次，Google scholar H因子54，獲中外專利20+項，轉讓授權18項，連續多年列全球top 2% 科學家。

TCM Theory Empowering the R&D and Post-Marketing Re-Evaluation of Dominant Chinese Materia Medica
中醫藥理論賦能中藥優勢品種研發與上市後再評價

Ms. LIN Na, Lead Researcher, Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences
中國中醫科學院中藥研究所首席研究員 林娜女士

Abstract 摘要

Under the guidance of TCM theory, we carry out research on combination of disease, syndrome and symptoms of chronic osteoarthropathy, aiming to establish a East-meets-West diagnosis system for the advantageous varieties of TCM. Scientific efficacy-connotations of the classic prescriptions and clinically effective prescriptions are explored to develop innovative new TCM drugs. A new technical platform was built for re-evaluation, re-discovery and re-innovation of Chinese patent medicines.

在中醫藥理論指導下，開展慢性骨關節病病 - 證 - 癥結合研究，建立中醫優勢病種的中西結合診療體系；研究經典名方和臨床效驗方的功效科學內涵，開發創新型中藥新藥；建立中成藥再評價再發現再創新的技術平台並應用。

Speaker's Biography 講者簡介

Na Lin, Chief Researcher of China Academy of Chinese Medical Sciences, Doctor of Tokyo University of Pharmacy, Japan, Leader of the high-level key discipline of clinical Pharmacology of Traditional Chinese Medicine under the State Administration of Traditional Chinese Medicine, Member of the National Pharmacopoeia Commission, Director of the Orthopedics and Traumatology Drug Research Professional Committee of the China Association of Chinese Medicine, Instructor of the National Program for Inheriting the Academic Experience of Senior TCM Experts, and Expert enjoying the Special Government allowance of The State Council.

林娜，中國中醫科學院首席研究員，日本東京藥科大學博士，國家中醫藥管理局臨床中藥學高水平重點學科帶頭人，國家藥典委員會委員，中國中藥協會骨傷科藥物研究專業委員會主任委員，全國老中醫藥專家學術經驗繼承工作指導老師，享受國務院政府特殊津貼專家。

A Soothing Cream Gel Improves the Range of Motion and Chronic Pain at Shoulder and Elbow: A Randomised, Double-blind and Placebo-Controlled Trial
天然舒緩霜凝膠改善肩部和肘部的活動範圍並緩解慢性疼痛的臨床療效評價研究

Prof. XIAN Yanfang Lisa, Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong
香港中文大學醫學院中醫學院助理教授 冼彥芳教授

Abstract 摘要

Upper limb problems are prevalent among the general population and often manifest as pain and mobility limitation. This study aimed to evaluate the efficacy and safety of the Vitas Soothing Cream Gel (VSCG) on patients with upper limb problems using a randomised, double-blind, placebo-controlled clinical trial (RCT). A total of 66 participants were recruited and randomly allocated to receive either the VSCG (n = 33) or the placebo (n = 33) for 2 consecutive weeks. The range of motion (ROM) of the shoulder or elbow from the baseline to week 2 and week 4 was used as the primary outcomes. The results indicated that the VSCG treatment significantly increased the elbow extension at week 4 as compared with the placebo group. No significant differences were found in the percentage changes of ROM from baseline to each time point between the VSCG group and the placebo group. The administration of VSCG was found to markedly improve the ROM limitation in patients at weeks 2 and 4 when compared with the those at baseline, including shoulder flexion ($p < 0.01$ for week 2 and $p < 0.001$ for week 4) and shoulder abduction ($p < 0.01$ for week 2 and $p < 0.001$ for week 4). Moreover, the VSCG treatment could significantly improve the Numeric Pain Rating Scale (NPRS) score in patients at week 2 when compared with the placebo group. No overt adverse effects were observed in both of the VSCG and the placebo groups. VSCG was found to be well-tolerated and could effectively ameliorate chronic pain and improve quality of life in patients with upper limb disorders.

上肢問題在一般人群中普遍存在，通常表現為疼痛和活動受限。本研究旨在透過隨機、雙盲、安慰劑對照臨床試驗 (RCT) 評估 Vitas 舒緩霜凝膠 (VSCG) 對上肢問題患者的有效性和安全性。共招募了 66 名參與者，並隨機分配接受連續兩週的 VSCG (n = 33) 或安慰劑 (n = 33) 治療。從基線到第 2 週和第 4 週的肩部或肘部活動範圍 (ROM) 被用作主要結果。結果表明，與安慰劑組相比，VSCG 治療在第 4 週顯著增加了肘關節伸展。 VSCG 組和安慰劑組之間從基線到每個時間點的 ROM 百分比變化沒有顯著差異。與基線相比，VSCG 治療可顯著改善患者在第 2 週和第 4 週的活動範圍限制，包括肩關節屈曲（第 2 週 $p < 0.01$，第 4 週 $p < 0.001$）和肩關節外展（第 2 週 $p < 0.01$，第 4 週 $p < 0.001$）。此外，與安慰劑組相比，VSCG 治療可顯著改善患者在第 2 週的數字疼痛評估量表 (NPRS) 評分。 VSCG 組和安慰劑組均未觀察到明顯的不良反應。 VSCG 耐受性良好，可有效緩解慢性疼痛並提高上肢疾病患者的生活品質。

Speaker's Biography 講者簡介

Dr. Yan-Fang Xian is the Assistant Professor and the Programme Director of Master Science in Chinese Medicine at School of Chinese Medicine, The Chinese University of Hong Kong. Dr. Xian obtained her PhD degree in 2013 from The Chinese University of Hong Kong. Her research interests are the pharmacology of Chinese medicine in Alzheimer's disease, various solid cancer and Metabolic disease. So far, Dr. Xian has published more than 100 original research articles based on her experimental findings in various SCI-listed academic journals such as Molecular cancer, Acta Pharmaceutica Sinica B, Journal of Experimental & Clinical Cancer Research, Journal of Advanced Research, Journal of Neuroinflammation, Brain, Behavior and Immunity with the H-index of 42 of Google Scholar. Over the past 5 years, she had successfully obtained more than ten external competitive grants. In addition, Dr. Xian listed as World's Top 2% Scientists by Stanford University.

冼彥芳博士現任香港中文大學中醫學院助理教授，中醫理學碩士課程課程主任。冼彥芳博士於 2013 年在香港中文大學獲得中醫哲學博士學位。近年來，冼博士及其團隊主要專注於中藥治療阿爾茨海默病、腫瘤及代謝性疾病的研究。到目前為止， 冼博士已在 Molecular cancer, Acta Pharmaceutica Sinica B, Journal of Experimental & Clinical Cancer Research, Journal of Advanced Research, Journal of Neuroinflammation, Brain, Behavior and Immunity 等國際知名雜誌上發表 SCI 論文 100 餘篇。其論文總引用次數超過 4,600 次， H 指數 : 42 (Google Scholar)，37 (Web of Science)。過去五年，冼博士以項目主持人的身份主持國家自然科學基金專案 (NSFC) 、廣東省自然科學基金面上專案 (NSFGD) 、香港醫務衛生局及創新科技局項目等 10 多項科研項目， 並擔任 Phytomedicine, Acta Materia Medica (AMM) 雜誌的編委，Chinese Medicine, Chinese Medicine and Culture 等多本雜誌的青年編委。此外，冼博士入選全球前 2% 頂尖科學家榜單（World's Top 2% Scientists）。